ArticlePloS one2015
Transgenic and mutation-based suppression of a berberine bridge enzyme-like (BBL) gene family reduces alkaloid content in field-grown tobacco.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Genome-wide identification, expression analysis of the JmjC gene family in tobacco and functional characterization of NtJMJ19 role in nicotine biosynthesis.BMC plant biology · 2026Article
- Complete nicotine biosynthesis reshapes the understanding of a classic alkaloid metabolic pathway.Frontiers in plant science · 2026Article
- Article
- Establishing a comprehensive web-based analysis platform for Nicotiana benthamiana genome and transcriptome.The Plant journal : for cell and molecular biology · 2025Article
- Development of an RNA virus vector for non-transgenic genome editing in tobacco and generation ofaBIOTECH · 2024Article
- Genetic regulation and manipulation of nicotine biosynthesis in tobacco: strategies to eliminate addictive alkaloids.Journal of experimental botany · 2024Review
- Comparative transcriptome analysis reveals nicotine metabolism is a critical component for enhancing stress response intensity of innate immunity system in tobacco.Frontiers in plant science · 2024Article
- An improved Nicotiana benthamiana bioproduction chassis provides novel insights into nicotine biosynthesis.The New phytologist · 2023Article
- Topping and grafting affect the alkaloid content and gene expression patterns of tobacco (Plant direct · 2023Article
- Knockout of a key gene of the nicotine biosynthetic pathway severely affects tobacco growth under field, but not greenhouse conditions.BMC research notes · 2022Article
- Natural and induced variations in transcriptional regulator genes result in low-nicotine phenotypes in tobacco.The Plant journal : for cell and molecular biology · 2022Article
- The Agronomic Traits, Alkaloids Analysis, FT-IR and 2DCOS-IR Spectroscopy Identification of the Low-Nicotine-Content Nontransgenic Tobacco Edited by CRISPR-Cas9.Molecules (Basel, Switzerland) · 2022Article
- Editing ofMolecular breeding : new strategies in plant improvement · 2022Article
- AJournal of advanced research · 2022Article
- Analyses of diverse low alkaloid tobacco germplasm identify naturally occurring nucleotide variability contributing to reduced leaf nicotine accumulation.Molecular breeding : new strategies in plant improvement · 2022Article
- Metabolization and sequestration of plant specialized metabolites in insect herbivores: Current and emerging approaches.Frontiers in physiology · 2022Review
- Impact of nicotine pathway downregulation on polyamine biosynthesis and leaf ripening in tobacco.Plant direct · 2021Article
- Discovery and Biosynthesis of Tetrachlorizine Reveals Enzymatic Benzylic Dehydrogenation via anJournal of the American Chemical Society · 2021Article
- Highly Efficient and Comprehensive Identification of Ethyl Methanesulfonate-Induced Mutations inFrontiers in plant science · 2021Article
- Reducing the nicotine content of tobacco by grafting with eggplant.BMC plant biology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Motivation exists to develop tobacco cultivars with reduced nicotine content for the purpose of facilitating compliance with expected tobacco product regulations that could mandate the lowering of nicotine levels per se, or the reduction of carcinogenic alkaloid-derived tobacco specific nitrosamines (TSNAs). A berberine bridge enzyme-like (BBL) gene family was recently characterized for N. tabacum and found to catalyze one of the final steps in pyridine alkaloid synthesis for this species. Because this gene family acts downstream in the nicotine biosynthetic pathway, it may represent an attractive target for genetic strategies with the objective of reducing alkaloid content in field-grown tobacco. In this research, we produced transgenic doubled haploid lines of tobacco cultivar K326 carrying an RNAi construct designed to reduce expression of the BBL gene family. Field-grown transgenic lines carrying functional RNAi constructs exhibited average cured leaf nicotine levels of 0.684%, in comparison to 2.454% for the untransformed control. Since numerous barriers would need to be overcome to commercialize transgenic tobacco cultivars, we subsequently pursued a mutation breeding approach to identify EMS-induced mutations in the three most highly expressed isoforms of the BBL gene family. Field evaluation of individuals possessing different homozygous combinations of truncation mutations in BBLa, BBLb, and BBLc indicated that a range of alkaloid phenotypes could be produced, with the triple homozygous knockout genotype exhibiting greater than a 13-fold reduction in percent total alkaloids. The novel source of genetic variability described here may be useful in future tobacco breeding for varied alkaloid levels.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.